Retatrutide: The Triple Agonist GLP-1 That Outperforms Everything
Retatrutide achieved 28.7% weight loss in Phase 3 trials — the highest ever recorded. Here's how the GLP-1/GIP/glucagon triple agonist works, what the data shows, and when it could reach patients.